# OnCo record immunovaccine (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/immunovaccine/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "immunovaccine" ;
  schema:name "Immunovaccine (IMV)"@en ;
  schema:alternateName "ImmunoVaccine Technologies, Inc."@en, "ImmunoVaccine Technologies"@en, "IMV Inc."@en, "IMV Inc"@en, "Immunovaccine Technologies Inc."@en ;
  schema:description "Immunovaccine (IMV) is a Canadian biotechnology company founded in 2000 in Halifax, Nova Scotia, whose survivin-targeted immunotherapy DPX-Survivac is tested with pembrolizumab and low-dose cyclophosphamide in two OnCo trials, in relapsed diffuse large B-cell lymphoma and in selected solid tumours."@en ;
  schema:url <https://onco.cc/companies/immunovaccine/>, <http://www.imvaccine.com/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <http://www.imvaccine.com/>, <https://www.wikidata.org/wiki/Q30282846>, <https://clinicaltrials.gov/search?lead=ImmunoVaccine%20Technologies%2C%20Inc.> ;
  onco:tag "ctgov-sponsor", "wave5-sponsor" ;
  schema:addressCountry "CA" ;
  onco:cancers <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/hcc/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/sclc/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/cyclophosphamide/> ;
  onco:companies <https://onco.cc/companies/merck/> ;
  onco:trials <https://onco.cc/trials/nct04920617/>, <https://onco.cc/trials/nct03836352/> .